GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (FRA:RN3N) » Definitions » Cyclically Adjusted Price-to-FCF

Arena Pharmaceuticals (FRA:RN3N) Cyclically Adjusted Price-to-FCF : (As of May. 21, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Arena Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Arena Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Arena Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Arena Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arena Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Arena Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arena Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arena Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Arena Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Arena Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Arena Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2021 is calculated as:

For example, Arena Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2021 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2021 (Change)*Current CPI (Dec. 2021)
=-1.745/117.6295*117.6295
=-1.745

Current CPI (Dec. 2021) = 117.6295.

Arena Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201203 -1.038 96.783 -1.262
201206 -0.528 96.819 -0.641
201209 -0.033 97.633 -0.040
201212 -0.343 96.871 -0.417
201303 -0.692 98.209 -0.829
201306 1.412 98.518 1.686
201309 0.012 98.790 0.014
201312 1.367 98.326 1.635
201403 -0.712 99.695 -0.840
201406 -1.172 100.560 -1.371
201409 -0.988 100.428 -1.157
201412 -0.916 99.070 -1.088
201503 -0.944 99.621 -1.115
201506 -0.908 100.684 -1.061
201509 -1.298 100.392 -1.521
201512 -0.575 99.792 -0.678
201603 -0.659 100.470 -0.772
201606 -0.597 101.688 -0.691
201609 -0.731 101.861 -0.844
201612 -0.319 101.863 -0.368
201703 -0.621 102.862 -0.710
201706 -0.762 103.349 -0.867
201709 -0.407 104.136 -0.460
201712 -0.189 104.011 -0.214
201803 -0.610 105.290 -0.681
201806 -0.659 106.317 -0.729
201809 -0.539 106.507 -0.595
201812 -0.601 105.998 -0.667
201903 12.718 107.251 13.949
201906 -0.997 108.070 -1.085
201909 -0.973 108.329 -1.057
201912 -1.106 108.420 -1.200
202003 -1.704 108.902 -1.841
202006 -1.309 108.767 -1.416
202009 -1.103 109.815 -1.181
202012 -1.503 109.897 -1.609
202103 -1.687 111.754 -1.776
202106 -1.284 114.631 -1.318
202109 -2.612 115.734 -2.655
202112 -1.745 117.630 -1.745

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arena Pharmaceuticals  (FRA:RN3N) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Arena Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Arena Pharmaceuticals (FRA:RN3N) Business Description

Traded in Other Exchanges
N/A
Address
136 Heber Avenue, Suite 204, Park City, UT, USA, 84060
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Arena Pharmaceuticals (FRA:RN3N) Headlines

No Headlines